Eagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Recommendation of “Hold” from Analysts
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has been assigned an average recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $62.33.
A number of research firms have recently commented on EGRX. Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 9th. ValuEngine downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $75.00 price objective (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Finally, Mizuho reissued a “sell” rating and set a $37.00 price target on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th.
Eagle Pharmaceuticals (EGRX) traded down $0.47 during trading hours on Tuesday, hitting $62.09. 319,800 shares of the stock were exchanged, compared to its average volume of 214,067. The company has a market cap of $926.48, a P/E ratio of 10.01 and a beta of 1.24. Eagle Pharmaceuticals has a one year low of $45.05 and a one year high of $97.15. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26.
Hedge funds have recently made changes to their positions in the stock. Municipal Employees Retirement System of Michigan lifted its holdings in Eagle Pharmaceuticals by 68.1% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after purchasing an additional 1,300 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Eagle Pharmaceuticals by 58.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock valued at $194,000 after acquiring an additional 908 shares in the last quarter. Schroder Investment Management Group acquired a new stake in Eagle Pharmaceuticals in the 3rd quarter valued at about $219,000. Foundry Partners LLC acquired a new stake in Eagle Pharmaceuticals in the 3rd quarter valued at about $224,000. Finally, Kopp Investment Advisors LLC increased its position in Eagle Pharmaceuticals by 0.3% in the 2nd quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock valued at $241,000 after acquiring an additional 10 shares in the last quarter.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.